Navigation Links
AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial

than 50% of men 60 years and over, with approximately 56 million cases in the U.S., Europe and Japan. In 2004, BPH treatment represented a market size of over US$4 billion. Contrary to most of the present treatments for BPH, cetrorelix is not associated with side-effects such as erectile dysfunction, loss of libido and chemical castration. According to Decision Resource, cetrorelix is currently the most advanced LHRH antagonist in development for the treatment of BPH.

About Cetrorelix

Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach. This peptide-based active substance was developed by the Company in cooperation with Nobel-Prize winner Professor Andrew Schally of the U.S. Veterans Administration in Miami and the University of Miami.

Cetrorelix is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through Merck Serono in the USA, Europe and in several other countries, as well as in Japan through Shionogi.

AEterna Zentaris is currently conducting a large Phase 3 program with cetrorelix in BPH while the Company's partner, Solvay is sponsoring a pivotal clinical program for endometriosis with this same compound.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a late-stage global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking s
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources ... awareness of the U.S. Food and Drug Administration,s (FDA) ... phosphate binder Velphoro, which was approved by the FDA ... chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Roche NimbleGen (SIX: RO, ROG; Pink Sheets: RHHBY ... genomic services provider Ambry Genetics has officially become a ... EZ Exome workflow. They will provide target-enrichment services ... sequencing services for genetic research. Ambry Genetics has passed ...
... Luminex Corporation (Nasdaq: LMNX ) today announced ... Conference to be held September 20 - 22, 2010, ...   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO ) ... president and chief executive officer, will begin at 8:00 ...
Cached Medicine Technology:Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 2Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 3Luminex Corporation to Present at UBS Global Life Sciences Conference 2
(Date:7/13/2014)... (PRWEB) July 14, 2014 MED-Ed Facilities ... at our next conference, April 7+8 in Boston at ... attended at the recent event. Presentations by individuals or ... , To review the types of sessions that were ... Submit your proposal today! , Conference Director, ...
(Date:7/13/2014)... 14, 2014 MillionaireCasket.com is a professional supplier ... excellent wood caskets are selling well in the global market. ... cherry caskets and launched a special offer for all ... prices, all the company’s cherry caskets are made with superb ... must for people to show respect to the departed saint. ...
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... Growth, Trends and Forecast 2013 - 2019 , Intraocular ... patients suffering from myopia or cataracts. The lenses are ... After the cataract surgery intraocular lens replaces the focusing ... switches with original crystalline lens to deliver the light ...
(Date:7/13/2014)... 13, 2014 Victorian Hotel has recently ... the rental of bikes for its "Cycle the City" ... Hotel to tour the area using a rental bicycle, ... enthusiasts love to call Vancouver home, as it is ... travel and picturesque journeys through the countryside. Vancouver hotel ...
(Date:7/13/2014)... July 13, 2014 Fuel additives are ... gasoline, diesel, jet fuel, kerosene, and so on, in ... responsible for reducing the corrosion effects caused by fuels ... added to any fuel, provide economies of scale in ... escalate the overall cost of the fuel products. , ...
Breaking Medicine News(10 mins):Health News:MED-Ed Facilities Conference Call for Speakers Open 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... , , , ... Michael Jackson,s death, reports of anxiety, depression, insomnia and fatigue have ... his reliance on prescription drugs. But Beverly Hills anti-aging consultants Karen ... Jackson could have been suffering from male menopause for years. You ...
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... supplier of branded generic and,innovative anti-cancer pharmaceuticals in China, ... quarter results on Monday, August 17, 2009,after the market ... Ren, and chief financial officer, Frank Zhigang Zhao, will,host ...
... ATHLETES SARAH WILL AND CHRIS WADDELL TO RIDE ON SEPT. ... of the greatest Paralympic athletes in the world have signed on to ... and Sarah Will both plan to ride in the event, raising money ... , , Waddell and Will join over a dozen ...
... , , SAN FRANCISCO, Aug. ... depression, according to a study just published in the Journal ... to higher risk for poor health outcomes and complications from ... of an ongoing study of healthy adults aged 65 and ...
... ... ... -- United Benefit Advisors (UBA), in partnership with the National Association of Health Underwriters (NAHU), ... regarding what,s happening now in the national health care reform debate., , , , ,Janet ...
... , ARLINGTON, Va., Aug. 5 ... service, and KnujOn.com , an Internet compliance ... (online advertisements) for Internet pharmacies displayed on bing.com. The report ... by the authors were fake or illegal Internet pharmacies. , ...
Cached Medicine News:Health News:SimplyAgeless Believes Michael Jackson Could Have Been Going Through 'Male Menopause' 2Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:Celebrity Paralympians Sign on to Kelly Brush Century Ride 2Health News:Celebrity Paralympians Sign on to Kelly Brush Century Ride 3Health News:Brain Fitness Reduces Risk of Onset of Depressive Symptoms 2Health News:UBA offers Free Webinar: NAHU Executive VP and CEO to Discuss Health Reform Bills 2Health News:UBA offers Free Webinar: NAHU Executive VP and CEO to Discuss Health Reform Bills 3Health News:Report: Microsoft Sponsoring Ads for Rogue Internet Pharmacies 2
... Easy Breeze Air Gel Dryer : Dry up ... 24 gels 8 10 cm without a ... rapid drying, or no heat for controlled drying ... transparent, dried gels. Add and remove gels at ...
Each GelAir™ system drying frame includes two main components, a plastic drying outer frame and a metal square inner frame, as well as 8 clamps per frame. Supplied as a set of two frames....
... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
... SGD5040 Slab Gel Dryer incorporates sturdy metal housing and ... The large surface area makes it perfect for drying ... Slim Profile 40cm x 50cm (W x D) ... Rates allows you to optimize your heating ...
Medicine Products: